Skip to Main Content

Paper Details

Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.
Neurooncol Adv
9
2021
89Zr, ADC, Depatux, Depatuxizumab mafadotin, EGFR, GBM, M12, anti-EGFR, brain tumor, depatuxizumab mafadotin, glioblastoma, gliomas, mice, patient, patients, solid tumors, tumor, tumors, zirconium-89

Datasets

Release 1.2